Brian L Erstad

Brian L Erstad

Department Head, Pharmacy Practice-Science
Professor, Pharmaceutical Sciences
Member of the Graduate Faculty
Professor, BIO5 Institute
Primary Department
Contact
(520) 626-4289

Work Summary

Brian Erstad’s research interests pertain to critical care medicine with an emphasis on patient safety and related outcomes research.

Research Interest

Brian L. Erstad, PharmD, FCCM, is currently a tenured professor and head of the Department of Pharmacy Practice and Science. He is also a center investigator for the Center for Health Outcomes and PharmacoEconomics Research and a co-director for the Arizona Clinical and Translational Research Graduate Certificate Program. His clinical responsibilities are performed at Banner-University Medical Center Tucson.Dr. Erstad’s research interests pertain to critical care medicine with an emphasis on patient safety and related outcomes research. He has authored more than 150 peer-reviewed articles and book chapters.Dr. Erstad has served on the board of directors of the American Society of Health-System Pharmacists and on numerous committees and task forces for other organizations including AHRQ, USP, Society of Critical Care Medicine and the American College of Chest Physicians. He is currently an ad hoc member of the FDA’s Drug Safety and Risk Management Advisory Committee, a steering committee member of the United States Critical Illness and Injury Trials (USCIIT) Group, and treasurer of the American College of Clinical Pharmacy.

Publications

Erstad, B. L. (1994). A rational approach to the management of acute pain states (part 2). Hospital Formulary, 29(8), 586-588+591.

Abstract:

Several classes of drugs can be used in the management of acute pain: acetaminophen, salicylates, miscellaneous mild analgesics, nonsteroidal anti- inflammatory drugs (NSAIDs), and opioids. Last month, the role of acetaminophen, salicylates, and NSAIDs was explored. This month, in the conclusion of the series, the role of opioids is discussed. Opioids are used for more severe pain states, with morphine being an inexpensive standard of comparison for this class of compounds. Also presented is this article is a sample formulary of analgesic agents and regimens for consideration by clinicians involved in direct patient care or in the formulary decision- making process.

Radosevich, J. J., Patanwala, A. E., & Erstad, B. L. (2013). Hepatotoxicity in obese versus nonobese patients with acetaminophen poisoning who are treated with intravenous N-acetylcysteine. American Journal of Therapeutics.

Abstract:

There is limited information regarding the outcomes associated with acetaminophen (APAP) poisoning in obese individuals. It is possible that patients who are obese are more susceptible to APAP-induced liver injury, thereby diminishing the efficacy of antidotes such as N-acetylcysteine (NAC). We evaluated the outcomes associated with APAP poisoning in obese versus nonobese adults who are treated with intravenous (IV) NAC. This was a retrospective cohort study conducted in a tertiary care, academic medical center. Adult patients with APAP toxicity, who were treated with IV NAC between June 2005 and August 2012, were included. The patients were categorized into 2 groups based on their body mass index (BMI): (1) obese (BMI ≥ 30.0 kg/m) versus (2) nonobese (BMI 18.5-24.9 kg/m). The primary outcome measure was the proportion of patients who developed hepatotoxicity (aspartate aminotransferase or alanine aminotransferase >1000 IU/L). A total of 80 patients were included in the final cohort (40 in each group). The median BMI for the obese and nonobese groups was 34.5 kg/m [interquartile range (IQR) 31.4-40.2] and 22.4 kg/m (IQR 21.2-23.9), respectively (P 0.001). Other than more white patients being present in the nonobese group, there were no other baseline differences between groups with regard to demographics, liver function tests, or coagulation studies. Obese patients received a median IV NAC dose of 291.5 mg/kg (IQR 270.8-300.7) compared with 300 mg/kg (IQR 287.8-301.9) in the nonobese group (P = 0.07). Hepatotoxicity occurred in 27.5% of the obese patients and 37.5% of the nonobese patients (P = 0.34). No adverse drug effects were noted in either group. Obese and nonobese patients being treated with IV NAC for APAP toxicity experienced similar rates of hepatotoxicity.

Erstad, B., & Erstad, B. L. (2003). The cost of enhanced acid suppression. Pharmacotherapy, 23(10 Pt 2).

Peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), and upper gastrointestinal bleeding are conditions that can make large demands on health care resources. Acid suppression is common therapy for these conditions. The economic implications of managing Helicobacter pylori-related PUD, GERD, and upper gastrointestinal bleeds were considered by several investigators. Economic analyses of drug regimens for PUD show that eradication is more cost effective than H2-receptor antagonist (H2RA) maintenance therapy. Although various eradication regimens have been compared, the results depend on a number of assumptions that preclude general conclusions regarding cost-effectiveness. Economic analyses related to GERD are hindered by the often chronic, relapsing nature of the disease, particularly once therapy is discontinued. Therefore, as with PUD, results of the economic analyses depend largely on initial assumptions relative to the model employed. With regard to upper gastrointestinal bleeding, proton pump inhibitors (PPIs) are potent acid suppressors that may help prevent rebleeding that was managed endoscopically. Further clinical and economic investigations of PPIs for stress ulcer prophylaxis are necessary. Cost-effectiveness studies comparing PPIs and H2RAs should focus on overall costs of managing these conditions and include economic benefits of preventing complications, and not on drug-acquisition costs alone.

Stricker, R. B., Vermeulen Jr., L. C., Ratko, T. A., Matuszewski, K. A., Erstad, B. L., & Brecher, M. E. (1995). What about plasma? [2]. Archives of Internal Medicine, 155(16), 1817-.
Erstad, B. L., & Tong, T. G. (1999). Evaluation of learning skills development and computer-assisted learning strategies associated with an orientation program. American Journal of Pharmaceutical Education, 63(2), 182-185.

Abstract:

The promotion of the importance of self-learning skills to students has paralleled the increasing use of computer technologies both in and out of the classroom. The purpose of this investigation was to evaluate an extended orientation session for incoming pharmacy students that included instruction in learning skills development and the use of computer-assisted instructional strategies. Pre- and post-assessment surveys containing questions with Likert-type response scales were completed by the students. Overall, the students found the sessions to be useful, with statistically significant improvements noted in their perceptions of the importance of learning techniques and use of the Internet for health-related purposes. Learning skills development and computer-assisted learning strategies are important aspects of a student's education, and this can be emphasized and initiated during orientation programs for incoming students.